Global Chronic Migraine Treatment Market: Introduction
Migraine is a painful episodic disorder that sometimes develops into a chronic form. It is one of the most prevalent neurological conditions in clinical practice. Chronic migraine (CM) is the natural development of migraine in its chronic form and has a headache frequency of 15 days per month with similar characteristics to migraine assaults. Many patients with chronic migraine also have overuse of medication, described as at least 10 days per month using a compound analgesic, opioid, triptan, or ergot derivative.
Obtain Report Details @ https://www.transparencymarketresearch.com/chronic-migraine-treatment-market.html
Global Chronic Migraine Treatment Market: Competitive Landscape
Founded in 1996, Novartis AG is among the top global pharmaceutical companies operating across all the geographies in almost all the specialties. It was established through the merger of Ciba-Geigy and Sandoz in 1996. It acquired Alcon, Inc. and expanded its base in eye care market. Novartis operates in patented pharmaceutical products, generic pharmaceuticals & biosimilars, and surgical and vision care segments. It offers many OTC as well as generic drugs for acute attack treatment of migraine. The company is investing into specialty prophylactic treatment drugs through its recent acquisitions and strategic collaborations.
Need an Overview of the Report on Chronic Migraine Treatment Market? Ask for the Brochure here
Incorporated in 1849, Pfizer Inc. is one of the leading biopharmaceutical companies. The company manages its commercial operations through two segments: Global Innovative Products and Global Essential Health. The global innovative products segment includes pharmaceutical sub-segment that focuses on novel pharmaceutical products, vaccines, oncology products, and consumer healthcare. The global essential health segment includes branded generics, generics, biosimilar, and infusion systems. Pfizer has expanded its neurosciences product portfolio through indigenous product developments and acquisitions across the market. The company offers OTC and prescription drugs for migraine treatment in the form of tablets as well as other forms.
Other key players operating in the global chronic migraine treatment market include AstraZeneca Plc., Allergan Plc., GlaxoSmithKline Plc., Eli Lilly & Company, Merck & Co., Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceutical Inc., Zosano Pharma Corporation, Alder BioPharmaceutical, Inc., Eisai Co., Ltd., and Avanir Pharmaceuticals, Inc.
Global Chronic Migraine Treatment Market: Dynamics
High Prevalence of Migraine and Increasing Transition from Episodic to Chronic Migraine to Drive the Market
According to a report by the World Health Organization (WHO), in 2013, migraine was the 6th most common cause for a year lost due to disability across the globe. According to a study, titled “Lifting the Burden”, conducted by World Health Organization and other prominent institutes in 2011, the prevalence of migraine across the globe was around 11.0%. Other independent studies suggest this prevalence to be around 14.7%. Prevalence of migraine among females is supposed to be 2 to 3 times more than in men. According to The Migraine Trust of the U.K., around 2% of the world population is estimated to be affected by chronic migraine. Furthermore, it is estimated that around 2 to 3% of episodic migraine patients transitioned to chronic migraine patients. Migraine attacks are triggered by various factors such as environmental change, hormonal imbalance, and dietary change. Rise in incidences of these triggering factors is projected to increase the number of episodic migraine patients, which in turn, is likely to increase chronic migraine patients’ population.
Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “Chronic Migraine Treatment Market” here
Ongoing Investment in Alternative Therapies to Restrain the Market
Various complementary alternative therapies are being practiced for chronic migraine treatment such as manual therapy, chiropractic, homeopathy, and Ayurveda. It is estimated that emerging and under-developed markets prominently use complementary alternative therapies for migraine treatment. According to a study conducted by physicians and scientists of Harvard Medical School of Boston, Massachusetts, U.S. in 2011, around 4.5% of adults in the U.S. relied on complementary alternative therapies to relieve migraine. Key industry players and research institutes are investing into development of new portable neuro-stimulating devices to offer abortive as well prophylactic treatment of migraine. Recent FDA approvals for such devices are projected to attract new players in this market. A few examples of such devices include sTMS mini by eNeuro, and Cefaly by Roxon.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453